New combo therapy aims to halt prostate cancer spread
NCT ID NCT03795207
First seen Apr 07, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned to receive SBRT alone or SBRT plus durvalumab for up to 12 months. The main goal is to see if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU de Brest
Brest, 29200, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Chbs Lorient
Lorient, 56100, France
-
Hospices Civils de Lyon
Pierre-Bénite, 69310, France
-
ICO
Saint-Herblain, 44805, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut de Cancérologie de Montpellier
Montpellier, 34298, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (an immunotherapy drug) and stereotactic body radiation therapy (SBRT, a precise high-dose radiation procedure)
What this could lead to
If successful, this could offer a new treatment option that delays cancer progression in men with a limited number of prostate cancer metastases.
What could go wrong
This is a phase II trial with only 96 participants, so results are preliminary. Adding immunotherapy to radiation may increase side effects, and the combination might not improve outcomes over radiation alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.